Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial

• Sunit Das,
• Arjun Sahgal,
• James R. Perry

Affiliations

Sunit Das

Division of Neurosurgery and Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada

Arjun Sahgal

Department of Radiation Oncology, Sunnybrook Hospital, University of Toronto, Toronto, ON, Canada

James R. Perry

Division of Neurology, Sunnybrook Hospital, University of Toronto, Toronto, ON, Canada